Evidence map›Paper›PMID 30003530›Full record

Trial reportClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2019

CalliSpheres® drug-eluting beads (DEB) transarterial chemoembolization (TACE) is equally efficient and safe in liver cancer patients with different times of previous conventional TACE treatments: a result from CTILC study.

X Zhang, J Zhou, D-D Zhu, J Huang, J-H Sun, T-F Li, C-S Shi, Z-C Sun, Q-M Hou, Z-Y Peng and 23 more

Abstract readClinical TrialMulticenter Study
PubMed Publisher
In one paragraph

Trial report in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
2.8field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 40 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

33 authors at 16 institutions in 1 country.

X ZhangInterventional Radiology Department, The First Affiliated Hospital, Zhejiang University, No. 79 Qingchun Road, Hangzhou, 310006, China.
J ZhouDepartment of Radiology, Hangzhou Cancer Hospital, No. 34 Yan Guan lane, Hangzhou, China.
D-D ZhuDepartment of Liver Oncology, Ningbo No. 2 Hospital, No. 41 Xibei Road, Ningbo, 315010, China.
J HuangDepartment of Hepatobiliary Surgery, Ningbo Medical Center Lihuili Easter Hospital, No. 1111 Jiangnan Road, Ningbo, 315000, China.
J-H SunDivision of Hepatobiliary and Pancreatic Surgery, Hepatobiliary and Pancreatic Interventional Treatment Center, The First Affiliated Hospital, Zhejiang University, No. 79 Qingchun Road, Hangzhou, 310006, China.
T-F LiDepartment of Radiology, Beilun District People's Hospital of Ningbo, No. 1288 Lushang East Road, Ningbo, 315826, China.
C-S ShiDepartment of Intervention, Ruian People's Hospital, The Third Affiliated Hospital of Wenzhou Medical University, No. 108 Wansong Road, Ruian, 325200, China.
Z-C SunDepartment of Radiology, The First Affiliated Hospital of Zhejiang Chinese Medical University, Zhejiang Hospital of TCM, No. 54 Youdian Road, Hangzhou, 310006, China.
Q-M HouDepartment of Radiology, Xixi Hospital of Hangzhou, Hangzhou 6th People's Hospital, Hengbu Street 2, Hangzhou, 310023, China.
Z-Y PengInterventional Radiology Department, The First Affiliated Hospital, Zhejiang University, No. 79 Qingchun Road, Hangzhou, 310006, China.
W-Q YuDepartment of Intervention, Zhejiang Provincial People's Hospital, People's Hospital of Hangzhou Medical College, No. 158 Shangtang Road, Hangzhou, 310000, China.
J-S JiDepartment of Radiology, Lishui Central Hospital, Lishui Hospital of Zhejiang University, The Fifth Affiliated Hospital of Wenzhou Medical University, No. 289 Kuocang Road, Lishui, 323000, China.
W-J GuDepartment of Intervention, Jiaxing Second Hospital, No. 1518 Huangcheng North Road, Jiaxing, 314000, China.
G-H ZhouDivision of Hepatobiliary and Pancreatic Surgery, Hepatobiliary and Pancreatic Interventional Treatment Center, The First Affiliated Hospital, Zhejiang University, No. 79 Qingchun Road, Hangzhou, 310006, China.
X-X XieInterventional Center, Xinchang People's Hospital, No. 117 Gushan Road, Xinchang, 312500, China.
X-H GuoDepartment of Intervention, Jinhua Municipal Central Hospital, Jinhua Hospital of Zhejiang University, No. 365 Renmin East Road, Jinhua, 321000, China.
G-H CaoDepartment of Radiology, Shulan (Hangzhou) Hospital, No. 848 Dongxin Road, Hangzhou, 310026, China.
Z-H YuDepartment of Vascular and Interventional Radiology, The Affiliated Hospital of Medical School of Ningbo University, No. 247 Renmin Road, Ningbo, 315020, China.
H-H XuDivision of Digestive Endoscopy, Yueqing City People's Hospital, No. 338 Qingyuan Road, Yueqing, 325600, China.
J FangDepartment of Hepatobiliary Surgery, Quzhou People's Hospital, No. 2 Zhongloudi, Quzhou, 324000, China.
S-H YingInterventional Radiology Department, The First Affiliated Hospital, Zhejiang University, No. 79 Qingchun Road, Hangzhou, 310006, China.
W-H HuDepartment of Intervention, The First Provincial Wenzhou Hospital of Zhejiang, The First Affiliated Hospital of Wenzhou Medical University, No. 2 Fuxue Lane, Wenzhou, 325099, China.
W-B JiDepartment of Radiology, Taizhou Hospital of Zhejiang Province, No. 150 Ximen Street, Linhai, 317000, China.
J HanDepartment of Intervention, Jiaxing First Hospital, No. 1882 Zhonghuan South Road, Jiaxing, 314001, China.
X WuDepartment of Radiology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, No. 3 Qingchun East Road, Hangzhou, 310016, China.
J-P ZhengDepartment of Intervention, Zhejiang Cancer Hospital, No. 1 Banshan East Road, Hangzhou, 310022, China.
J LuoDepartment of Intervention, Zhejiang Cancer Hospital, No. 1 Banshan East Road, Hangzhou, 310022, China.
Y-T ChenDepartment of Intervention, Zhejiang Cancer Hospital, No. 1 Banshan East Road, Hangzhou, 310022, China.
T-Y HuDepartment of Intervention, Zhejiang Provincial People's Hospital, People's Hospital of Hangzhou Medical College, No. 158 Shangtang Road, Hangzhou, 310000, China.
L LiDepartment of Liver Oncology, Ningbo No. 2 Hospital, No. 41 Xibei Road, Ningbo, 315010, China.
H-J HuDepartment of Radiology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, No. 3 Qingchun East Road, Hangzhou, 310016, China.
H-J DuDepartment of Intervention, Dongyang People's Hospital, No. 60 Wuning West Road, Dongyang, 322100, China. 425183318@qq.com.
G-L ShaoDepartment of Intervention, Zhejiang Cancer Hospital, No. 1 Banshan East Road, Hangzhou, 310022, China. shaoguoliang1@163.com.ORCID http://orcid.org/0000-0002-0315-8896
First Affiliated Hospital Zhejiang University · CNWenzhou Medical University · CNZhejiang Cancer Hospital · CNFirst Hospital of Jiaxing · CNNingbo No. 2 Hospital · CNSir Run Run Shaw Hospital · CNZhejiang Provincial People's Hospital · CNHangzhou Cancer Hospital · CNHangzhou Xixi hospital · CNJinhua Central Hospital · CNNingbo Medical Center Lihuili Hospital · CNNingbo University · CNQuzhou City People's Hospital · CNXintai People's Hospital · CNYueqing People's Hospital · CNZhejiang Chinese Medical University · CN

Funding

National Nature Science Foundation of China 81371658Zhejiang Provincial Natural Science Foundation of China LZ18H180001
6 · The paper itself

Abstract

purposeTo assess the efficacy and safety of drug-eluting beads transarterial chemoembolization (DEB-TACE) in liver cancer patients with different times of previous conventional transarterial chemoembolization (cTACE) treatments.

methods367 liver cancer patients about to receive DEB-TACE treatment were enrolled in this prospective cohort study. All patients were divided into no previous cTACE group (NPC group), 1-2 times previous cTACE group (PC group) and triple or above previous cTACE group (TPC group) according to the times of previous cTACE treatments.

resultsThere was no difference in complete response (CR) (P = 0.671) and objective response rate (ORR) (P = 0.062) among three groups. Additionally, no difference in overall survival (OS) among groups (P = 0.899) was found. As to liver function, most liver function indexes were deteriorative at 1 week after DEB-TACE operation, but returned to baseline at 1-3 months after DEB-TACE operation in all three groups, while percentage of abnormal total bile acid (TBA) patients was higher in TPC group than NPC and PC groups at 1-3 month post-DEB-TACE (P = 0.018). As for safety profiles, the incidence of pain during DEB-TACE operation was lower in TPC group compared to NPC and PC groups (P = 0.005), while no difference of other adverse events was found during and 1 month post-DEB-TACE treatment among three groups.

conclusionDEB-TACE treatment was equally efficient and tolerated in liver cancer patients with different times of previous cTACE treatments.

Indexed as

AdultAgedAntibiotics, AntineoplasticChemoembolization, TherapeuticDoxorubicinDrug CarriersFemaleHumansKaplan-Meier EstimateLiver NeoplasmsMaleMicrospheresMiddle AgedNeoplasm Recurrence, LocalTreatment OutcomeAntibiotics, AntineoplasticDoxorubicinDrug CarriersDrug-eluting beads transarterial chemoembolization (DEB-TACE)EfficacyLiver cancerPrevious cTACE treatmentSafety

Identifiers

PMID30003530
OpenAlexW2859687572

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.